MCID: NNT008
MIFTS: 34

Neonatal Abstinence Syndrome

Categories: Respiratory diseases, Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to dementia - subcortical and eosinophilia-myalgia syndrome. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways is Interleukin-4 and 13 signaling. The drugs Guaifenesin and Loperamide have been mentioned in the context of this disorder. Affiliated tissues include breast and heart.

Related Diseases for Neonatal Abstinence Syndrome

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
2
Loperamide Approved Phase 4 53179-11-6 3955
3
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
4
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
5
Opium Approved, Illicit Phase 4 8008-60-4
6
Phenobarbital Approved Phase 4,Phase 3 50-06-6 4763
7
Clonidine Approved Phase 4,Phase 2,Phase 3,Phase 1 4205-90-7 2803
8
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
9
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
12 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
13 Anticonvulsants Phase 4,Phase 3
14 Antidiarrheals Phase 4
15 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
17 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
18 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
19 Excitatory Amino Acid Antagonists Phase 4,Phase 3
20 Excitatory Amino Acids Phase 4,Phase 3
21 GABA Agents Phase 4,Phase 3
22 GABA Modulators Phase 4,Phase 3
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Hypnotics and Sedatives Phase 4,Phase 3
25 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Adrenergic Agents Phase 4,Phase 2,Phase 3
30 Adrenergic Agonists Phase 4,Phase 2,Phase 3
31 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3
32 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
33 Antihypertensive Agents Phase 4,Phase 2,Phase 3
34 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1
36 Sympatholytics Phase 4,Phase 2,Phase 3
37 Opium Poppy Nutraceutical Phase 4
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
39
Chlorpromazine Approved, Vet_approved Phase 3 50-53-3 2726
40
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
41
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 5760 446220
42
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
43 Narcotic Antagonists Phase 3,Phase 2,Phase 1
44 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
45 Antiemetics Phase 3,Phase 1,Phase 2
46 Antipsychotic Agents Phase 3,Phase 1,Phase 2
47 Dopamine Agents Phase 3
48 Dopamine Antagonists Phase 3
49 Psychotropic Drugs Phase 3,Phase 1,Phase 2
50 Tranquilizing Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show all 43)

id Name Status NCT ID Phase Drugs
1 Treatment of Neonatal Abstinence Syndrome Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
2 NAS Treatment - Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal Completed NCT01804075 Phase 4 Methadone;Morphine
4 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Recruiting NCT02851303 Phase 4 Morphine;Methadone
5 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Not yet recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
6 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
7 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
8 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
9 How to Treat Opiate Withdrawal in Neonates Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
10 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
11 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
12 Improving Outcomes in Neonatal Abstinence Syndrome Active, not recruiting NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
13 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Enrolling by invitation NCT03097484 Phase 3 lavender and chamomile essential oils
14 Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
15 Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed NCT00510016 Phase 2 Clonidine HCL
16 RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
17 The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Completed NCT00218621 Phase 2
18 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed NCT01801475 Phase 1, Phase 2 Ondansetron
19 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Recruiting NCT01965704 Phase 2 Ondansetron;Placebo
20 Methadone Demonstration Project Recruiting NCT03134703 Phase 2 Methadone;Morphine
21 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Recruiting NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
22 Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) Enrolling by invitation NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
23 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome Not yet recruiting NCT02872077 Phase 1, Phase 2
24 Maternal Buprenorphine-naloxone Treatment and the Infant Not yet recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
25 Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
26 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
27 The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome Completed NCT01754324 Phase 1 Methadone
28 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies Unknown status NCT02062151
29 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
30 Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers Completed NCT01889121
31 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111
32 Fetal Neurobehavior in Poly-drug Dependent Women Completed NCT00653692
33 Fetal Neurobehavioral Development in Methadone Maintained Pregnancies Completed NCT00067184
34 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
35 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
36 Weighted Blankets With Infants With NAS Recruiting NCT03113656
37 Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics Recruiting NCT02863601
38 Opioid Dependence Treatment Therapies in Pregnancy Recruiting NCT03098407 Buprenorphine;Methadone
39 Donor Human Milk in Neonatal Abstinence Syndrome Active, not recruiting NCT02182973
40 Physiology and Therapeutic Management of Neonatal Abstinence Syndrome Enrolling by invitation NCT02768844
41 Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome Enrolling by invitation NCT02801331
42 Buprenorphine Dose Adjustments and Gestational Age Enrolling by invitation NCT03028883
43 Clonidine for Neonatal Abstinence Syndrome Study Terminated NCT01175668 Clonidine;Phenobarbital

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

39
Breast, Heart

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 238)
id Title Authors Year
1
An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. ( 28562267 )
2017
2
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. ( 28594753 )
2017
3
Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. ( 28685864 )
2017
4
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877015 )
2017
5
Re: Neonatal Abstinence Syndrome and High School Performance. ( 28814555 )
2017
6
Neonatal Abstinence Syndrome Management: A Review of Recent Evidence. ( 28814260 )
2017
7
The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. ( 28073819 )
2017
8
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877016 )
2017
9
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28880503 )
2017
10
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28880502 )
2017
11
The economic burden of neonatal abstinence syndrome in the United States. ( 28612362 )
2017
12
In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature. ( 28543284 )
2017
13
Neonatal Abstinence Syndrome Better Treated With Buprenorphine. ( 28655009 )
2017
14
Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study. ( 28682319 )
2017
15
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. ( 27983768 )
2017
16
Opioid Use and Abuse and Neonatal Abstinence Syndrome. ( 28726245 )
2017
17
Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal. ( 28561904 )
2017
18
Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs. ( 27926654 )
2017
19
Re: Neonatal Abstinence Syndrome and High School Performance. ( 28814556 )
2017
20
Evaluation of the Effectiveness of Two Morphine Protocols to Treat Neonatal Abstinence Syndrome in a Level II Nursery in a Community Hospital. ( 28594450 )
2017
21
The Effect of Morphine Dosing on Length of Stay in Neonatal Abstinence Syndrome - An Alternative Viewpoint. ( 28949409 )
2017
22
A management strategy that reduces NICU admissions and decreases charges from the front line of the neonatal abstinence syndrome epidemic. ( 28682317 )
2017
23
The Genomics of Neonatal Abstinence Syndrome. ( 28879171 )
2017
24
Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. ( 26791055 )
2016
25
The Association Between Breastfeeding and Length of Hospital Stay Among Infants Diagnosed with Neonatal Abstinence Syndrome: A Population-Based Study of In-Hospital Births. ( 27529500 )
2016
26
Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-2013. ( 26879950 )
2016
27
Neonatal Abstinence Syndrome: A Growing Problem. ( 27636688 )
2016
28
Nonpharmacologic Management of Neonatal Abstinence Syndrome: An Integrative Review. ( 27636695 )
2016
29
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations. ( 26974659 )
2016
30
Rural and Urban Differences in Neonatal Abstinence Syndrome and Maternal Opioid Use, 2004 to 2013. ( 27942711 )
2016
31
A Qualitative Study of Family Experience With Hospitalization for Neonatal Abstinence Syndrome. ( 27647475 )
2016
32
Neonatal abstinence syndrome and the gastrointestinal tract. ( 27876117 )
2016
33
Active Somatic and Psychic Ear Acupuncture Points in Newborn Infants with Neonatal Abstinence Syndrome. ( 27486672 )
2016
34
NICU Culture of Care for Infants with Neonatal Abstinence Syndrome: A Focused Ethnography. ( 27636693 )
2016
35
Comparison of Neonatal Abstinence Syndrome Manifestations in Preterm Versus Term Opioid-Exposed Infants. ( 27611018 )
2016
36
Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome. ( 26588259 )
2016
37
Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. ( 27513154 )
2016
38
Neonatal Abstinence Syndrome Following Tianeptine Dependence During Pregnancy. ( 26659818 )
2016
39
Improving Care for Neonatal Abstinence Syndrome. ( 27244809 )
2016
40
A Cohort Comparison of Buprenorphine versus Methadone Treatment forA Neonatal Abstinence Syndrome. ( 26703873 )
2016
41
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All. ( 27636696 )
2016
42
Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. ( 26799428 )
2016
43
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center. ( 27723910 )
2016
44
Neonatal Abstinence Syndrome. ( 28002715 )
2016
45
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations. ( 27244045 )
2016
46
Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. ( 27669331 )
2016
47
Incidence of neonatal abstinence syndrome triples in US. ( 27528262 )
2016
48
Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome. ( 27636691 )
2016
49
Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help? ( 27386303 )
2016
50
NANN Provides Education About Neonatal Abstinence Syndrome and Zika Virus Infection and Prepares Neonatal Nurses to Be Advocates for Their Profession and Their Patients. ( 27391568 )
2016

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

Pathways related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.68 OPRD1 OPRM1

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 COMT LY96 OPRD1 OPRK1 OPRM1
2 dendrite GO:0030425 9.43 COMT OPRK1 OPRM1
3 perikaryon GO:0043204 9.37 OPRK1 OPRM1
4 neuron projection GO:0043005 9.33 OPRD1 OPRK1 OPRM1
5 axon terminus GO:0043679 9.32 OPRD1 OPRK1
6 intrinsic component of plasma membrane GO:0031226 8.96 LY96 OPRD1
7 dendrite membrane GO:0032590 8.62 OPRD1 OPRM1

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.69 OPRD1 OPRK1 OPRM1
2 response to lipopolysaccharide GO:0032496 9.67 COMT LY96 OPRM1
3 neuropeptide signaling pathway GO:0007218 9.61 OPRD1 OPRK1 OPRM1
4 cellular response to lipopolysaccharide GO:0071222 9.58 LY96 OPRK1
5 response to ethanol GO:0045471 9.58 OPRK1 OPRM1
6 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.58 OPRD1 OPRK1 OPRM1
7 locomotory behavior GO:0007626 9.57 OPRK1 OPRM1
8 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 OPRD1 OPRM1
9 response to cocaine GO:0042220 9.55 OPRK1 OPRM1
10 response to radiation GO:0009314 9.54 OPRK1 OPRM1
11 sensory perception of pain GO:0019233 9.54 OPRD1 OPRK1 OPRM1
12 response to morphine GO:0043278 9.52 OPRK1 OPRM1
13 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.5 OPRD1 OPRK1 OPRM1
14 estrous cycle GO:0044849 9.48 OPRK1 OPRM1
15 sensory perception GO:0007600 9.46 OPRK1 OPRM1
16 eating behavior GO:0042755 9.33 OPRD1 OPRK1 OPRM1
17 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.26 OPRK1 OPRM1
18 opioid receptor signaling pathway GO:0038003 9.13 OPRD1 OPRK1 OPRM1
19 regulation of sensory perception of pain GO:0051930 8.92 COMT OPRD1 OPRK1 OPRM1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.33 OPRD1 OPRK1 OPRM1
2 neuropeptide binding GO:0042923 9.13 OPRD1 OPRK1 OPRM1
3 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....